SCHEMBL6483726

SCHEMBL6483726

COc1cccc(CNc2cccc3c2oc2ccccc23)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 4/20 0.56
ABCG2 Q9UNQ0 2/20 0.56
EGFR P00533 3/20 0.50
IGF1R P08069 3/20 0.50
ACP1 P24666 1/20 0.50
GRM2 Q14416 1/20 0.49
APP P05067 1/20 0.47
VKORC1 Q9BQB6 1/20 0.47
HDAC8 Q9BY41 1/20 0.45
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
ALDH1A1 P00352 2/20 0.45
MAPT P10636 2/20 0.45
HPGD P15428 2/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
KDM4E B2RXH2 1/20 0.45
LMNA P02545 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
POLB P06746 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6495698 0.91 ABCB1 (0.52) ABCB1ABCG2EGFRIGF1RACP1
SCHEMBL6494308 0.87 EGFR (0.59) EGFRIGF1RACP1GRM2APP
SCHEMBL6483561 0.82 HDAC8 (0.55) EGFRIGF1RACP1HDAC8MEN1
SCHEMBL6482996 0.81 MAPT (0.49) ABCB1ABCG2EGFRIGF1RHDAC8
SCHEMBL6493255 0.80 MAPT (0.55) ABCB1ABCG2EGFRIGF1RAPP
SCHEMBL6484427 0.77 HDAC8 (0.57) ACP1HDAC8MEN1KMT2AALDH1A1
SCHEMBL6493932 0.75 ADRA2C (0.55) ABCB1EGFRIGF1RMEN1KMT2A
SCHEMBL6492811 0.74 HPGD (0.43) EGFRIGF1RHDAC8MEN1KMT2A
SCHEMBL6490363 0.74 ALDH1A1 (0.55) EGFRIGF1RVKORC1MEN1KMT2A
SCHEMBL5537824 0.74 ABCB1 (0.66) ABCB1ABCG2ACP1GRM2APP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050075332-A1 Tricyclic compounds with antiviral activity WARNER LAMBERT COMPANY 2005-04-07 US claimed
US-6800656-B2 Tricyclic compounds and method of treating herpes virus WARNER LAMBERT COMPANY 2004-10-05 US claimed
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 US claimed
EP-1248777-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2002-10-16 EP claimed
WO-2001051479-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2001-07-19 WO claimed
US-20050075332-A1 Tricyclic compounds with antiviral activity WARNER LAMBERT COMPANY 2005-04-07 US disclosed
US-6800656-B2 Tricyclic compounds and method of treating herpes virus WARNER LAMBERT COMPANY 2004-10-05 US disclosed
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus HDAC8, ZC3HAV1, ZCCHC8 ABCB1 2836/4885ABCG2 1897/4885EGFR 1980/4885
US-20050075332-A1 Tricyclic compounds with antiviral activity HDAC8, CDK8, ZC3HAV1 ABCB1 3373/4885ABCG2 1303/4885EGFR 1272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.